Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and ...

The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...

Merck & Co. Inc. MRK shares are up during Monday’s premarket session as the company is evolving its Human Health organization to enhance commercial execution across various therapeutic areas. This ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. Ticker: Spirit Airlines climbing out of bankruptcy; FedEx ...

Merck evolves human health operating structure to support portfolio execution: Rahway, New Jersey Tuesday, February 24, 2026, 13:00 Hrs [IST] Merck, known as MSD outside of the Un ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its effort to diversify ahead of patent loss for its blockbuster cancer drug ...

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...